Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.

The Company is raising $10,000,000 (with the right to accept oversubscriptions up to an additional $2,000,000) in new funds to continue the repurposing and commercialisation of Exenatide through execution of a series of development activities.

Interested investors are encouraged to read the attached Prospectus.


Level 1, 38 Rowland St

Subiaco, Perth WA 6008




+61 (08) 6382 0137

ACN 632145334


Copyright 2019 Invex Therapeutics Ltd